457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)
oleh: Enriqueta Felip, Jianda Yuan, Lawrence Fong, Charu Aggarwal, Razvan Cristescu, Myung-Ju Ahn, Alexandra Snyder, Matthew Hellmann, Roy Herbst, Martin Gutierrez, Edward Garon, Jong-Seok Lee, Julie Kobie, Matthew Gubens, Daniel Shao Weng Tan, Joanne WY Chiu, James Chih-Hsin Yang, Giovanna Finocchiaro, Alexander Luft, Gregory Landers, Andrea Basso, Hua Ma, John Palcza
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.